Filtered By:
Cancer: Cancer
Drug: Fortamet
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1065 results found since Jan 2013.
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma
Endocrinology. 2023 Sep 20:bqad139. doi: 10.1210/endocr/bqad139. Online ahead of print.ABSTRACTOral squamous cell carcinoma (OSCC) is one of the most common malignancies with high mortality, posing a great threat to both human physical and mental health. With the advancement of scientific research, a variety of cancer therapies have been used for OSCC treatment. However, the prognosis of OSCC shows no significant improvement. Metformin has been recognized as the first-line drug for the treatment of diabetes, and recent studies have shown that metformin has a remarkable suppressive effect on tumor progression. Metformin can...
Source: Endocrinology - September 22, 2023 Category: Endocrinology Authors: Jiayi Liu Jing Zhao Xue Qiao Source Type: research
Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion
Autophagy. 2023 Sep 21. doi: 10.1080/15548627.2023.2259216. Online ahead of print.ABSTRACTCrizotinib, a small-molecule tyrosine kinase inhibitor targeting ALK, MET and ROS1, is the first-line drug for ALK-positive metastatic non-small cell lung cancer and is associated with severe, sometimes fatal, cases of cardiac failure, which increases the risk of mortality. However, the underlying mechanism remains unclear, which causes the lack of therapeutic strategy. We established in vitro and in vivo models for crizotinib-induced cardiotoxicity and found that crizotinib caused left ventricular dysfunction, myocardial injury and p...
Source: Autophagy - September 21, 2023 Category: Cytology Authors: Zhifei Xu Zezheng Pan Ying Jin Zizheng Gao Feng Jiang Huangxi Fu Xueqin Chen Xiaochen Zhang Hao Yan Xiaochun Yang Bo Yang Qiaojun He Peihua Luo Source Type: research
Boningmycin induces AMPK-mediated endoplasmic reticulum-associated degradation of PD-L1 protein in human cancer cells
In conclusion, it is the first report demonstrating that BON decreases PD-L1 protein level through AMPK-mediated endoplasmic reticulum-associated degradation pathway. These findings will benefit the clinical transformation of BON and aid in the elucidation of molecular mechanism of BLM-related compounds.PMID:37717372 | DOI:10.1016/j.intimp.2023.110905
Source: International Immunopharmacology - September 17, 2023 Category: Allergy & Immunology Authors: Juan Zhang Jincai Wang Yue Shang Yang Chen Shuzhen Chen Qiyang He Source Type: research
Metformin inhibits self-renewal of colorectal cancer stem cells by inhibiting mitochondrial oxidative phosphorylation
CONCLUSION: Metformin reduces mitochondrial oxidative phosphorylation and ROS levels by inhibiting mitochondrial complex Ⅰ, thereby suppressing Wnt signaling pathway to reduce selfrenewal ability of colorectal CSCs.PMID:37712263 | PMC:PMC10505579 | DOI:10.12122/j.issn.1673-4254.2023.08.03
Source: Journal of Southern Medical University - September 15, 2023 Category: Universities & Medical Training Authors: C Yan S Liu Q Song Y Hu Source Type: research
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
J Clin Oncol. 2023 Sep 11:JCO2300296. doi: 10.1200/JCO.23.00296. Online ahead of print.ABSTRACTClinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 rando...
Source: Clinical Breast Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Pamela J Goodwin Bingshu E Chen Karen A Gelmon Timothy J Whelan Marguerite Ennis Julie Lemieux Jennifer A Ligibel Dawn L Hershman Ingrid A Mayer Timothy J Hobday Judith M Bliss Priya Rastogi Manuela Rabaglio-Poretti Alastair M Thompson Daniel W Rea Paul M Source Type: research
Fight Aging! Newsletter, September 11th 2023
This article reviews the current regulatory role of miR-7 in inflammation and related diseases, including viral infection, autoimmune hepatitis, inflammatory bowel disease, and encephalitis. It expounds on the molecular mechanism by which miR-7 regulates the occurrence of inflammatory diseases. Finally, the existing problems and future development directions of miR-7-based intervention on inflammation and related diseases are discussed to provide new references and help strengthen the understanding of the pathogenesis of inflammation and related diseases, as well as the development of new strategies for clinical interventi...
Source: Fight Aging! - September 10, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Ultra-efficient radio-immunotherapy for reprogramming the hypoxic and immunosuppressive tumor microenvironment with durable innate immune memory
Biomaterials. 2023 Sep 5;302:122303. doi: 10.1016/j.biomaterials.2023.122303. Online ahead of print.ABSTRACTRadiosensitization efficacy of conventional tumor radiosensitizers has been frequently limited by insufficient competence for tumor microenvironment (TME) regulation and unfavorable cellular uptake at biological barriers. Here, we reported an ultra-efficient radiotherapy (RT) strategy by synthesizing an extracellular vesicles (EVs)-encapsulated hollow MnO2 to load metformin (Met@HMnER). It demonstrated significant RT enhancement by morphological control of catalyst and cellular respiratory depression against conventi...
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Jichun Yang Chong Zhang Xiaohui Chen Daijun Zhou Zixin Sun Ruyan Niu Ying Zhu Hengyi Chen Liu Wang Yi Chen Yuhan Wang Yunqian Fu Ningyu Ma Jianjun Li Yang Luo Source Type: research
Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action
This study aims to investigate the effect of metformin and aspirin and their combination of them on A549 and PC3 cell lines. Metformin and aspirin were investigated separately and in combination on two cancer cell lines, A549 and PC3. The examined groups include the negative control of untreated cells and the positive control of cisplatin and drugs at concentrations of 15, 10, and 20 μg/ mL to investigate the mechanism of oxidative stress factors (reactive oxygen species, lipid peroxidation, Glutathione (GSH)) and apoptosis (lactate dehydrogenase). The results showed that aspirin, metformin, and their combination could af...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Farzaneh Motafeghi Romina Shahsavari Parham Mortazavi Aysan Babaei Pouria SamadiMojaveri Omid Abed Khojasteh Mohammad Shokrzadeh Source Type: research
